Au Hua Endoscope (688212.SH) released its semi-annual report for 2024, and the company achieved revenue of 3... during the reporting period.
According to the semi-annual report for 2024 released by Au Hua Endoscope (688212.SH), the company achieved operating revenue of 0.354 billion yuan, a year-on-year increase of 22.29%; the net profit attributable to shareholders of the listed company was 5.6616 million yuan, a year-on-year decrease of 85.13%; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.3458 million yuan; and the basic earnings per share was 0.04 yuan/share.
During the reporting period, the company's operating revenue increased by 22.29% compared to the same period last year, mainly due to the company's increased product promotion, updating and upgrading its products based on clinical needs, and continuously expanding its coverage of hospitals at all levels. At the same time, the company's brand influence is also continuously rising, which has a positive promotion effect on its operation.